Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 246

1.

What Came First-the Virus or the Egg?

Doms RW.

Cell. 2017 Feb 23;168(5):755-757. doi: 10.1016/j.cell.2017.02.012.

2.

Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques.

Li H, Wang S, Kong R, Ding W, Lee FH, Parker Z, Kim E, Learn GH, Hahn P, Policicchio B, Brocca-Cofano E, Deleage C, Hao X, Chuang GY, Gorman J, Gardner M, Lewis MG, Hatziioannou T, Santra S, Apetrei C, Pandrea I, Alam SM, Liao HX, Shen X, Tomaras GD, Farzan M, Chertova E, Keele BF, Estes JD, Lifson JD, Doms RW, Montefiori DC, Haynes BF, Sodroski JG, Kwong PD, Hahn BH, Shaw GM.

Proc Natl Acad Sci U S A. 2016 Jun 14;113(24):E3413-22. doi: 10.1073/pnas.1606636113. Epub 2016 May 31.

3.

Making Bunyaviruses Talk: Interrogation Tactics to Identify Host Factors Required for Infection.

Riblett AM, Doms RW.

Viruses. 2016 May 13;8(5). pii: E130. doi: 10.3390/v8050130. Review.

4.

Platelet Factor 4 Inhibits and Enhances HIV-1 Infection in a Concentration-Dependent Manner by Modulating Viral Attachment.

Parker ZF, Rux AH, Riblett AM, Lee FH, Rauova L, Cines DB, Poncz M, Sachais BS, Doms RW.

AIDS Res Hum Retroviruses. 2016 Jul;32(7):705-17. doi: 10.1089/AID.2015.0344. Epub 2016 Mar 15.

5.

A Haploid Genetic Screen Identifies Heparan Sulfate Proteoglycans Supporting Rift Valley Fever Virus Infection.

Riblett AM, Blomen VA, Jae LT, Altamura LA, Doms RW, Brummelkamp TR, Wojcechowskyj JA.

J Virol. 2015 Nov 18;90(3):1414-23. doi: 10.1128/JVI.02055-15. Print 2016 Feb 1.

6.

Antibodies elicited by yeast glycoproteins recognize HIV-1 virions and potently neutralize virions with high mannose N-glycans.

Zhang H, Fu H, Luallen RJ, Liu B, Lee FH, Doms RW, Geng Y.

Vaccine. 2015 Sep 22;33(39):5140-7. doi: 10.1016/j.vaccine.2015.08.012. Epub 2015 Aug 13.

7.

The major cellular sterol regulatory pathway is required for Andes virus infection.

Petersen J, Drake MJ, Bruce EA, Riblett AM, Didigu CA, Wilen CB, Malani N, Male F, Lee FH, Bushman FD, Cherry S, Doms RW, Bates P, Briley K Jr.

PLoS Pathog. 2014 Feb 6;10(2):e1003911. doi: 10.1371/journal.ppat.1003911. eCollection 2014 Feb.

8.

Simultaneous zinc-finger nuclease editing of the HIV coreceptors ccr5 and cxcr4 protects CD4+ T cells from HIV-1 infection.

Didigu CA, Wilen CB, Wang J, Duong J, Secreto AJ, Danet-Desnoyers GA, Riley JL, Gregory PD, June CH, Holmes MC, Doms RW.

Blood. 2014 Jan 2;123(1):61-9. doi: 10.1182/blood-2013-08-521229. Epub 2013 Oct 25.

9.

Quantitative phosphoproteomics reveals extensive cellular reprogramming during HIV-1 entry.

Wojcechowskyj JA, Didigu CA, Lee JY, Parrish NF, Sinha R, Hahn BH, Bushman FD, Jensen ST, Seeholzer SH, Doms RW.

Cell Host Microbe. 2013 May 15;13(5):613-623. doi: 10.1016/j.chom.2013.04.011.

10.

Phenotypic properties of transmitted founder HIV-1.

Parrish NF, Gao F, Li H, Giorgi EE, Barbian HJ, Parrish EH, Zajic L, Iyer SS, Decker JM, Kumar A, Hora B, Berg A, Cai F, Hopper J, Denny TN, Ding H, Ochsenbauer C, Kappes JC, Galimidi RP, West AP Jr, Bjorkman PJ, Wilen CB, Doms RW, O'Brien M, Bhardwaj N, Borrow P, Haynes BF, Muldoon M, Theiler JP, Korber B, Shaw GM, Hahn BH.

Proc Natl Acad Sci U S A. 2013 Apr 23;110(17):6626-33. doi: 10.1073/pnas.1304288110. Epub 2013 Mar 29.

11.

Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5.

Parker ZF, Iyer SS, Wilen CB, Parrish NF, Chikere KC, Lee FH, Didigu CA, Berro R, Klasse PJ, Lee B, Moore JP, Shaw GM, Hahn BH, Doms RW.

J Virol. 2013 Mar;87(5):2401-11. doi: 10.1128/JVI.02964-12. Epub 2012 Dec 26.

12.

Kruppel-like factor 2 modulates CCR5 expression and susceptibility to HIV-1 infection.

Richardson MW, Jadlowsky J, Didigu CA, Doms RW, Riley JL.

J Immunol. 2012 Oct 15;189(8):3815-21. doi: 10.4049/jimmunol.1201431. Epub 2012 Sep 17.

13.

HIV: cell binding and entry.

Wilen CB, Tilton JC, Doms RW.

Cold Spring Harb Perspect Med. 2012 Aug 1;2(8). pii: a006866. doi: 10.1101/cshperspect.a006866. Review.

14.

Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7.

Parrish NF, Wilen CB, Banks LB, Iyer SS, Pfaff JM, Salazar-Gonzalez JF, Salazar MG, Decker JM, Parrish EH, Berg A, Hopper J, Hora B, Kumar A, Mahlokozera T, Yuan S, Coleman C, Vermeulen M, Ding H, Ochsenbauer C, Tilton JC, Permar SR, Kappes JC, Betts MR, Busch MP, Gao F, Montefiori D, Haynes BF, Shaw GM, Hahn BH, Doms RW.

PLoS Pathog. 2012;8(5):e1002686. doi: 10.1371/journal.ppat.1002686. Epub 2012 May 31.

15.

Novel approaches to inhibit HIV entry.

Didigu CA, Doms RW.

Viruses. 2012 Feb;4(2):309-24. doi: 10.3390/v4020309. Epub 2012 Feb 21. Review.

16.

Molecular mechanisms of HIV entry.

Wilen CB, Tilton JC, Doms RW.

Adv Exp Med Biol. 2012;726:223-42. doi: 10.1007/978-1-4614-0980-9_10. Review.

PMID:
22297516
17.

Efficient production of Hantaan and Puumala pseudovirions for viral tropism and neutralization studies.

Higa MM, Petersen J, Hooper J, Doms RW.

Virology. 2012 Feb 20;423(2):134-42. doi: 10.1016/j.virol.2011.08.012. Epub 2011 Dec 29.

18.

Quantitative phosphoproteomics of CXCL12 (SDF-1) signaling.

Wojcechowskyj JA, Lee JY, Seeholzer SH, Doms RW.

PLoS One. 2011;6(9):e24918. doi: 10.1371/journal.pone.0024918. Epub 2011 Sep 20.

19.

Primary infection by a human immunodeficiency virus with atypical coreceptor tropism.

Jiang C, Parrish NF, Wilen CB, Li H, Chen Y, Pavlicek JW, Berg A, Lu X, Song H, Tilton JC, Pfaff JM, Henning EA, Decker JM, Moody MA, Drinker MS, Schutte R, Freel S, Tomaras GD, Nedellec R, Mosier DE, Haynes BF, Shaw GM, Hahn BH, Doms RW, Gao F.

J Virol. 2011 Oct;85(20):10669-81. doi: 10.1128/JVI.05249-11. Epub 2011 Aug 10.

20.

Phenotypic and immunologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins.

Wilen CB, Parrish NF, Pfaff JM, Decker JM, Henning EA, Haim H, Petersen JE, Wojcechowskyj JA, Sodroski J, Haynes BF, Montefiori DC, Tilton JC, Shaw GM, Hahn BH, Doms RW.

J Virol. 2011 Sep;85(17):8514-27. doi: 10.1128/JVI.00736-11. Epub 2011 Jun 29.

21.

Fusing HIV and chemokine receptors.

Doms RW.

J Immunol. 2011 Jun 1;186(11):6073-5. doi: 10.4049/jimmunol.1100982. No abstract available.

22.

Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases.

Wilen CB, Wang J, Tilton JC, Miller JC, Kim KA, Rebar EJ, Sherrill-Mix SA, Patro SC, Secreto AJ, Jordan AP, Lee G, Kahn J, Aye PP, Bunnell BA, Lackner AA, Hoxie JA, Danet-Desnoyers GA, Bushman FD, Riley JL, Gregory PD, June CH, Holmes MC, Doms RW.

PLoS Pathog. 2011 Apr;7(4):e1002020. doi: 10.1371/journal.ppat.1002020. Epub 2011 Apr 14.

23.

Rift valley fever virus infection of human cells and insect hosts is promoted by protein kinase C epsilon.

Filone CM, Hanna SL, Caino MC, Bambina S, Doms RW, Cherry S.

PLoS One. 2010 Nov 24;5(11):e15483. doi: 10.1371/journal.pone.0015483.

24.

Yeast-elicited cross-reactive antibodies to HIV Env glycans efficiently neutralize virions expressing exclusively high-mannose N-linked glycans.

Agrawal-Gamse C, Luallen RJ, Liu B, Fu H, Lee FH, Geng Y, Doms RW.

J Virol. 2011 Jan;85(1):470-80. doi: 10.1128/JVI.01349-10. Epub 2010 Oct 20.

25.

Immunology. Prime, boost, and broaden.

Doms RW.

Science. 2010 Aug 27;329(5995):1021-2. doi: 10.1126/science.1195116. No abstract available.

PMID:
20798304
26.

A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5.

Tilton JC, Wilen CB, Didigu CA, Sinha R, Harrison JE, Agrawal-Gamse C, Henning EA, Bushman FD, Martin JN, Deeks SG, Doms RW.

J Virol. 2010 Oct;84(20):10863-76. doi: 10.1128/JVI.01109-10. Epub 2010 Aug 11.

27.

A Potent, Broad-Spectrum Antiviral Agent that Targets Viral Membranes.

Wojcechowskyj JA, Doms RW.

Viruses. 2010 May;2(5):1106-9. doi: 10.3390/v2051106. Epub 2010 May 4.

28.

HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cells.

Pfaff JM, Wilen CB, Harrison JE, Demarest JF, Lee B, Doms RW, Tilton JC.

J Virol. 2010 Jul;84(13):6505-14. doi: 10.1128/JVI.00374-10. Epub 2010 Apr 21.

29.

HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry.

Tilton JC, Amrine-Madsen H, Miamidian JL, Kitrinos KM, Pfaff J, Demarest JF, Ray N, Jeffrey JL, Labranche CC, Doms RW.

AIDS Res Hum Retroviruses. 2010 Jan;26(1):13-24. doi: 10.1089/aid.2009.0132.

30.

Antibodies against Manalpha1,2-Manalpha1,2-Man oligosaccharide structures recognize envelope glycoproteins from HIV-1 and SIV strains.

Luallen RJ, Agrawal-Gamse C, Fu H, Smith DF, Doms RW, Geng Y.

Glycobiology. 2010 Mar;20(3):280-6. doi: 10.1093/glycob/cwp184. Epub 2009 Nov 17.

31.

Adaptive mutations in a human immunodeficiency virus type 1 envelope protein with a truncated V3 loop restore function by improving interactions with CD4.

Agrawal-Gamse C, Lee FH, Haggarty B, Jordan AP, Yi Y, Lee B, Collman RG, Hoxie JA, Doms RW, Laakso MM.

J Virol. 2009 Nov;83(21):11005-15. doi: 10.1128/JVI.01238-09. Epub 2009 Aug 19.

32.

Entry inhibitors in the treatment of HIV-1 infection.

Tilton JC, Doms RW.

Antiviral Res. 2010 Jan;85(1):91-100. doi: 10.1016/j.antiviral.2009.07.022. Epub 2009 Aug 14. Review.

PMID:
19683546
33.

Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities.

Pugach P, Ray N, Klasse PJ, Ketas TJ, Michael E, Doms RW, Lee B, Moore JP.

Virology. 2009 May 10;387(2):296-302. doi: 10.1016/j.virol.2009.02.044. Epub 2009 Mar 20.

34.

A yeast glycoprotein shows high-affinity binding to the broadly neutralizing human immunodeficiency virus antibody 2G12 and inhibits gp120 interactions with 2G12 and DC-SIGN.

Luallen RJ, Fu H, Agrawal-Gamse C, Mboudjeka I, Huang W, Lee FH, Wang LX, Doms RW, Geng Y.

J Virol. 2009 May;83(10):4861-70. doi: 10.1128/JVI.02537-08. Epub 2009 Mar 4.

35.

Enhanced exposure of the CD4-binding site to neutralizing antibodies by structural design of a membrane-anchored human immunodeficiency virus type 1 gp120 domain.

Wu L, Zhou T, Yang ZY, Svehla K, O'Dell S, Louder MK, Xu L, Mascola JR, Burton DR, Hoxie JA, Doms RW, Kwong PD, Nabel GJ.

J Virol. 2009 May;83(10):5077-86. doi: 10.1128/JVI.02600-08. Epub 2009 Mar 4.

36.
37.

Baseline resistance of primary human immunodeficiency virus type 1 strains to the CXCR4 inhibitor AMD3100.

Harrison JE, Lynch JB, Sierra LJ, Blackburn LA, Ray N, Collman RG, Doms RW.

J Virol. 2008 Dec;82(23):11695-704. doi: 10.1128/JVI.01303-08. Epub 2008 Sep 17.

38.

An engineered Saccharomyces cerevisiae strain binds the broadly neutralizing human immunodeficiency virus type 1 antibody 2G12 and elicits mannose-specific gp120-binding antibodies.

Luallen RJ, Lin J, Fu H, Cai KK, Agrawal C, Mboudjeka I, Lee FH, Montefiori D, Smith DF, Doms RW, Geng Y.

J Virol. 2008 Jul;82(13):6447-57. doi: 10.1128/JVI.00412-08. Epub 2008 Apr 23.

39.

Focused dampening of antibody response to the immunodominant variable loops by engineered soluble gp140.

Selvarajah S, Puffer BA, Lee FH, Zhu P, Li Y, Wyatt R, Roux KH, Doms RW, Burton DR.

AIDS Res Hum Retroviruses. 2008 Feb;24(2):301-14. doi: 10.1089/aid.2007.0158.

PMID:
18284327
40.

N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virus.

Dey AK, David KB, Ray N, Ketas TJ, Klasse PJ, Doms RW, Moore JP.

Virology. 2008 Mar 1;372(1):187-200. Epub 2007 Nov 26.

41.

V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies.

Laakso MM, Lee FH, Haggarty B, Agrawal C, Nolan KM, Biscone M, Romano J, Jordan AP, Leslie GJ, Meissner EG, Su L, Hoxie JA, Doms RW.

PLoS Pathog. 2007 Aug 24;3(8):e117.

42.

Modulation of HIV and SIV neutralization sensitivity by DC-SIGN and mannose-binding lectin.

Marzi A, Mitchell DA, Chaipan C, Fisch T, Doms RW, Carrington M, Desrosiers RC, Pöhlmann S.

Virology. 2007 Nov 25;368(2):322-30. Epub 2007 Jul 30.

43.

Replication-competent variants of human immunodeficiency virus type 2 lacking the V3 loop exhibit resistance to chemokine receptor antagonists.

Lin G, Bertolotti-Ciarlet A, Haggarty B, Romano J, Nolan KM, Leslie GJ, Jordan AP, Huang CC, Kwong PD, Doms RW, Hoxie JA.

J Virol. 2007 Sep;81(18):9956-66. Epub 2007 Jul 3.

44.

Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors.

Dhillon AK, Donners H, Pantophlet R, Johnson WE, Decker JM, Shaw GM, Lee FH, Richman DD, Doms RW, Vanham G, Burton DR.

J Virol. 2007 Jun;81(12):6548-62. Epub 2007 Apr 4.

45.

Identification of a novel C-terminal cleavage of Crimean-Congo hemorrhagic fever virus PreGN that leads to generation of an NSM protein.

Altamura LA, Bertolotti-Ciarlet A, Teigler J, Paragas J, Schmaljohn CS, Doms RW.

J Virol. 2007 Jun;81(12):6632-42. Epub 2007 Apr 4.

46.

Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors.

Ray N, Harrison JE, Blackburn LA, Martin JN, Deeks SG, Doms RW.

J Virol. 2007 Apr;81(7):3240-50. Epub 2007 Jan 24.

47.

Kinetic studies of HIV-1 and HIV-2 envelope glycoprotein-mediated fusion.

Gallo SA, Reeves JD, Garg H, Foley B, Doms RW, Blumenthal R.

Retrovirology. 2006 Dec 4;3:90.

48.

A simian immunodeficiency virus V3 loop mutant that does not efficiently use CCR5 or common alternative coreceptors is moderately attenuated in vivo.

Pöhlmann S, Münch J, Aziz S, Reeves JD, Otto C, Leslie GJ, Hofmann H, Puffer BA, Baribaud F, Marzi A, Gramberg T, Chen Z, Stolte N, Haaft PT, Heeney JL, Stahl-Hennig C, Mätz-Rensing K, Schneider T, Doms RW, Kirchhoff F.

Virology. 2007 Apr 10;360(2):275-85. Epub 2006 Nov 28.

49.

A plea for justice for jailed medical workers.

Ahuja SK, Aiuti F, Berkhout B, Biberfeld P, Burton DR, Colizzi V, Deeks SG, Desrosiers RC, Dierich MP, Doms RW, Emerman M, Gallo RC, Girard M, Greene WC, Hoxie JA, Hunter E, Klein G, Korber B, Kuritzkes DR, Lederman MM, Malim MH, Marx PA, McCune JM, McMichael A, Miller C, Miller V, Montagnier L, Montefiori DC, Moore JP, Nixon DF, Overbaugh J, Pauza CD, Richman DD, Saag MS, Sattentau Q, Schooley RT, Shattock R, Shaw GM, Stevenson M, Trkola A, Wainberg MA, Weiss RA, Wolinsky S, Zack JA.

Science. 2006 Nov 10;314(5801):924-5. Epub 2006 Oct 24. No abstract available.

PMID:
17062652
50.

The neutralizing antibody response against West Nile virus in naturally infected horses.

Sánchez MD, Pierson TC, Degrace MM, Mattei LM, Hanna SL, Del Piero F, Doms RW.

Virology. 2007 Mar 15;359(2):336-48. Epub 2006 Oct 20.

Supplemental Content

Support Center